Home
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Hematology (41)
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Takeda Pharmaceutical Company Limited announced that 9 hematology abstracts are being presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and...
Read MoreVideos
01 Mar, 2020
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved